ILUMETRI, also known by its generic name tildrakizumab, is a prescription medication used in the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It belongs to a class of drugs known as monoclonal antibodies, specifically targeting the interleukin-23 (IL-23) protein, a key player in the inflammatory process that contributes to the development of psoriasis. By inhibiting IL-23, ILUMETRI helps to reduce the inflammation, scaling, and thickness of psoriatic plaques, leading to an improvement in symptoms and skin appearance. It is administered through subcutaneous injections, and its dosing schedule typically involves an initial dose followed by subsequent doses at specific intervals. As with any medication, it is important to use ILUMETRI under the guidance of a healthcare professional to ensure its safe and effective use.